The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, September 2018
|
| DOI | 10.2147/dmso.s126855 |
| Pubmed ID | |
| Authors |
Ryan T Hurt, Manpreet S Mundi, Jon O Ebbert |
| Abstract |
Obesity is a global epidemic that is a leading cause of preventable death. In addition to lifestyle modification, there are numerous obesity treatments for clinicians to consider, including medications. Lorcaserin immediate release/extended release (IR/XR) is a US Food and Drug Administration approved medication for overweight and obese patients to be used with lifestyle modifications. Lorcaserin is thought to reduce weight by targeting the serotonin (5HT2c) system to induce satiety. Lorcaserin IR has been shown to be effective in reducing weight in overweight (body mass index [BMI] > 27 kg/m2) and obese (BMI > 30 kg/m2) participants in three large Phase III trials. In addition, lorcaserin has been shown to reduce post-cessation weight gain and improved smoking cessation in a randomized placebo-controlled trial. A recent meta-analysis suggested in overweight diabetic patients lorcaserin may be added to first-line oral hypoglycemic medications to enhance reduction in glycated hemoglobin. Lorcaserin is generally well tolerated with the most common side effect being headache, which is typically self-limiting. Lorcaserin XR (once daily) was recently approved and has been shown to be bioequivalent to lorcaserin IR (twice daily) in a pivotal study. Lorcaserin XRs, main advantage over the IR formulation is the once daily dosing regimen, which likely would lead to improved adherence and thus improved clinical effectiveness. The present review will evaluate the lorcaserin clinical studies (obesity, diabetes, and addiction), XR bioequivalence studies, pharmacogenomics of the serotonin (5HT2c) system, and adherence data in once daily versus twice daily medications. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 11% |
| Student > Master | 6 | 11% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Bachelor | 4 | 7% |
| Student > Doctoral Student | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 23 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 21% |
| Nursing and Health Professions | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Neuroscience | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 25 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2018.
All research outputs
#17,350,971
of 25,461,852 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#611
of 1,184 outputs
Outputs of similar age
#223,297
of 345,970 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#12
of 18 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,970 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.